That leaves 220 workers to focus on Theranos' business plans.
Ronny Gal, Sanford C. Bernstein senior analyst, discusses his outlook for the biotech sector.
CNBC's Meg Tirrell discusses what to expect from the JPMorgan Health Care Conference 2017.
A judge ruling blocks Sanofi and partner Regeneron from selling their cholesterol drug, which is a victory for Amgen. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell takes a look at Kaléo's naloxone, and how new technology of administering drugs are driving prices higher.
CNBC's Meg Tirrell reports on how first responders deal with emergency opioid overdose calls, and potential headwinds.
These are the stocks posting the largest moves after the bell.
David Nelson, Belpointe asset management, and Luke Timmerman, Timmerman Report, forecast 2017 trends in biotech and if the space is something to consider for your portfolio.
Ronny Gal, Sanford C. Bernstein analyst, shares his expectations on the biotech sector in 2017.
CNBC's Meg Tirrell takes a look at what investors can expect from the biotech and pharma sectors in the new year.
Beijia Ma, equity strategist at BofA Merrill Lynch, explains the nuances of the autonomous vehicle market, adding that sensor technology is crucial to its success.
Shares of Synergy Pharmaceuticals soar after positive drug trial results. CNBC's Morgan Brennan reports.
CNBC's Meg Tirrell looks at which stocks in the IBB of more than $1 billion market cap have the biggest potential upside.
CNBC's Meg Tirrell reports on how pharmaceutical companies, governments and nonprofits are better preparing for the next major infectious disease outbreak.
Nineteen U.S. senators send a letter to President-elect Donald Trump in an attempt to bring down drug prices. CNBC's Meg Tirrell reports.
"Fast Money" trader David Seaburg pitches to the desk why to buy under-the-radar biotech stock AbbVie.
CNBC's Meg Tirrell speaks to new Biogen CEO Michel Vounatsos about the outlook of the company, Eli Lilly's experimental Alzheimer's drug and his expectations of the Trump administration.
Clovis Oncology shares jumped 15 percent Monday after the FDA approved Rubraca (rucaparib), the company's advanced ovarian cancer drug.
After a five-month search, Biogen names Michel Vounatsos its next CEO. CNBC's Meg Tirrell reports.
Shares of Gilead sink after-hours following a court order to pay Merck $2.5 billion in Hepatitis C royalties. CNBC's Meg Tirrell reports. The "Fast Money" traders weigh in.